Introduction: The fluocinolone acetonide (FA) 
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INTRODUCTION
The term 'uveitis' comprises a group of intraocular inflammatory conditions that directly or indirectly affects the iris, ciliary body, and choroid, collectively known as the uveal tract, as well as the retina, optic nerve, and vitreous [1] [2] [3] [4] . In most cases, the etiology of uveitis is unknown; however, it can be associated with autoimmune disease, infection (viral, fungal, or parasitic), or trauma [2] [3] [4] [5] [6] .
Uveitis results in significant visual impairment and is thought to account for 10-15% of all cases of total blindness in the United States (US) and developed world [1, 4, [6] [7] [8] . While posterior uveitis accounts for only 20% of the estimated 1 in 500 people in the US with uveitis [1] , it is the more severe form of the disease. The primary causes of vision loss in patients with uveitis are cystoid macular edema (CME) and/or cataract [1, 4, 7] , with CME being the leading cause of vision loss in posterior uveitis. Treatments aimed at reducing CME are therefore effective in the treatment of uveitis.
Corticosteroids are considered the mainstay of noninfectious uveitis treatment [4, 9] . However, since the disease is typically chronic in nature, patients often require long-term repeated treatment with either topical or systemic corticosteroids [10, 11] . In severe cases of uveitis, multiple rounds of sub-Tenon or intravitreal corticosteroid injections as well as systemic corticosteroids may be necessary. The potential for complications such as endophthalmitis, vitreous hemorrhage, and retinal detachment following use of repeated intravitreal injections is substantial [12, 13] . Systemic corticosteroids require high dosages to achieve therapeutic concentrations in the eye and are associated with systemic side effects including hypertension, hyperglycemia, and increased susceptibility to infection [14, 15] . Immunosuppressive agents can be an effective treatment option, but are associated with serious and potentially life-threatening systemic adverse events (AEs) such as renal and hepatic failure and bone marrow suppression [9, 16] . Thus, such therapy is The sustained release of FA was previously reported to result in long-term, continuous control of inflammation [17, 18] , and the implant is therefore considered to be particularly suitable for patients with chronic inflammation due to NIPU.
The FA intravitreal implant was evaluated in three large multicenter clinical trials during the course of its development. Thirty-four-week [19] and 3-year results [18] of the first trial and 2-year results [20] of the second trial have been published previously. Both of these trials were conducted in predominantly non-Asian patients. Herein, we report the results of the third trial which evaluated the safety and efficacy of the 0.59-mg implant (marketed formulation) and a 2.1-mg FA implant in a predominantly Asian population with chronic, recurrent, unilateral or bilateral NIPU.
METHODS

Study Design
This was a 3-year multicenter, randomized, double-masked, dose-controlled safety and efficacy study of two FA intravitreal implantsone containing 0.59 mg and the other 2.1 mgin patients with chronic, recurrent, unilateral or The FA implants and surgical implantation procedure have been described in detail elsewhere [11, 18, 19] . Briefly, the polymerbased intravitreal implant contains a sustained- One week post-implantation, patients discontinued use of existing therapy for ocular inflammation as follows: (1) consequently, patients were evaluated with fluorescein angiography at screening, at week 8, week 34, and 1, 2, and 3 years using a standardized protocol with macular hyperfluorescence evaluated by masked readers as described previously [19] .
Efficacy Outcomes
Three types of comparisons were utilized in the study: (1) Recurrences were considered 'observed' when they were seen and recorded by study investigators, whereas they were considered 'imputed' when a subject was not seen within 10 weeks of the final scheduled visit.
Secondary efficacy outcomes were evaluated using the fellow nonimplanted eye as a control for the study eye and included: rate of and time to post-implantation recurrence of uveitis; change in BCVA; and area of CME using a 300-s fluorescein angiogram, and the proportion of eyes requiring systemic therapy or periocular injections to control inflammation using the pre-implantation comparison group data. Secondary efficacy outcomes included observed and imputed recurrence data where applicable.
Safety Outcomes
Safety outcomes included intraocular pressure (IOP), lens opacity estimated using the lens opacity classification system (LOCS) II, visual field, ocular and nonocular AEs, visual acuity, and ophthalmoscopic examination findings. 
Statistical Analyses
Statistical analyses were performed using SAS, withdrawal in 17 patients (n = 4, 0.59-mg implant; n = 13, 2.1-mg implant). Other reasons for withdrawal included loss to followup (n = 3, 0.59-mg implant; n = 1, 2.1-mg implant), death (n = 1, 0.59-mg implant; n = 2, 2.1-mg implant), subject condition no Table 3 Uveitis recurrence rates in implanted eyes pre-and post-implantation 
Uveitis Recurrence Rates
Uveitis recurrence rates for implanted eyes are shown in Table 3 . Recurrence rates in eyes treated with the 0.59-mg implant decreased significantly from the 1-year pre-implantation period to the 1-, 2-, and 3-year postimplantation period (P\0.0001 for all).
Recurrence rates for eyes treated with the 2.1-mg implant were significantly decreased from 
Time to Uveitis Recurrence
Kaplan-Meier analysis was used to evaluate time to recurrence of uveitis for implanted and nonimplanted eyes (Fig. 1) . The difference in time to recurrence of uveitis in implanted versus nonimplanted eyes was statistically significant for both dose groups (P\0.0001).
Recurrences for fellow nonimplanted eyes occurred much earlier than recurrences for implanted eyes. In the 0.59-mg FA implant group, uveitis recurrence in nonimplanted fellow eyes increased rapidly during the first 150 days after implantation of the contralateral eye, whereas for implanted eyes, a significant increase in uveitis recurrence was not seen until Kaplan-Meier analysis of implanted study eyes versus nonimplanted fellow eyes performed only for patients with bilateral disease yielded similar results: the time to recurrence of uveitis was significantly longer in implanted eyes than in fellow nonimplated eyes (P\0.0001, data not shown).
Adjunctive Therapy
The FA intravitreal implant reduced the need for adjunctive uveitis treatment. The proportion of patients requiring adjunctive treatment to control inflammation before and after FA implantation is shown in Table 4 
Cystoid Macular Edema
The mean area of CME measured on the 300-s fluorescein angiogram decreased from 38.0 mm 2 at screening to 9.3 mm 2 at the 34-week post-implantation visit in eyes that received the 0.59-mg implant. For the remainder of the 3-year post-implantation follow-up period in the 0.59-mg FA implant group, mean area of CME for implanted eyes continued to decrease to a mean 3-year CME area of 6.2 or 4.6 mm 2 using the last observation carried forward (LOCF). Eyes receiving the 2.1-mg implant experienced a reduction in the area of CME from 46.1 mm 2 at screening to 4.7 mm 2 at the 34-week post-implantation visit; however, this increased to 15.3 mm 2 by the 3-year visit (LOCF mean CME was 12.8 mm 2 ). In nonimplanted fellow eyes for both dose groups combined, the mean area of CME fluctuated Comparisons were made during the entire 1-year pre-implantation period and the 1-and 3-year post-implantation periods. One fellow eye (2.1-mg FA implant group) was prosthetic, and thus the sample size for fellow eyes was 238) c P value for 1 year pre-implantation data compared with 3 year postimplantation data within a narrow range over the 3-year postimplantation follow-up period and the area of CME at screening was very similar to that at the 3-year visit (approximately 15-20 mm 2 ). The number of patients experiencing any reduction in the area of CME between baseline and 3-year post-implantation is presented in Table 5 .
Safety Outcomes
Mean (±SD) exposure to FA was 1,038.9 (188.0) days in the 0.59-mg implant group and 1,016.1 (225.1) days in the 2.1-mg implant group.
Treatment-emergent ocular AEs (including perioperative events) were reported in 99.6%
(238/239) of implanted study eyes and in 81.6%
(195/239) of fellow nonimplanted eyes. Table 6 presents the most frequently occurring AEs in implanted study eyes and in nonimplanted fellow eyes in each of the implant dose groups and combined. Among the most frequently observed ocular AEs reported for implanted study eyes, elevated IOP and cataract are commonly associated with ocular steroid use. Other frequently reported AEs in implanted eyes (e.g., eye pain, hypotony, conjunctival hemorrhage, and hyperemia) appear to be primarily associated with surgery. In fellow eyes, the most frequently observed ocular AEs (decreased visual acuity, cataract formation, and eye pain) were in part due to uveitic inflammation experienced when the effects of 
Intraocular Pressure
Lens Opacification
The rate of C2-grade changes in lens opacities from baseline for subcapsular, nuclear, and Table 5 Number of patients experiencing reduction in the area of CME between baseline and the 3-year post-implantation visit
Implant dose
Implanted eyes Nonimplanted eyes P value a N Eyes experiencing reduction in CME, n (%) N Eyes experiencing reduction in CME, n (%) 
Visual Fields
Visual field sensitivity was quantified as the mean deficit (MD), measured in decibels (dB). 
Nonocular Adverse Events
Nonocular AEs were reported in 86.6% (207/ 239) of patients in both dose groups combined. 
DISCUSSION
The results of this study demonstrate that the FA intravitreal implant is effective in the treatment of NIPU in a predominantly Asian patient population. The FA intravitreal implant effectively reduced rates of uveitis recurrence and improved visual outcomes compared to nonimplanted fellow eyes. The degree of posterior uveitis is CME [21, 22] . The ability of the FA implant to reduce CME through control of inflammation led to good visual acuity outcomes. These improved visual acuity outcomes were observed despite the formation of cataracts in the majority of implanted patients. Cataract formation and progress are common in eyes with uveitis and attributable both to the inflammatory progress and to the chronic use of corticosteroids to control the disease. [16] In this study, nearly all (94.9%) were seen in implanted than nonimplanted eyes (P B 0.0084) [23] .
Elevated IOP is also common in uveitic eyes due to the occlusion of aqueous outflow by inflammatory debris and/or formation of peripheral anterior synechia [24, 25] . Herbert et al. [26] reported the prevalence of elevated IOP in uveitis patients to be as high as 41.8%; with 29.8% of cases requiring treatment to manage the elevated IOP. The proportion of implanted eyes experiencing elevations in IOP in this study was higher (67.8% and 71.3% of eyes in the 0.59-and the 2.1-mg implant groups, respectively), due to the fact that corticosteroid treatment itself may also lead to reduced aqueous outflow through a variety of mechanisms [27, 28] . 
